MX347981B - Composicion de anticuerpos pan-her. - Google Patents

Composicion de anticuerpos pan-her.

Info

Publication number
MX347981B
MX347981B MX2013004899A MX2013004899A MX347981B MX 347981 B MX347981 B MX 347981B MX 2013004899 A MX2013004899 A MX 2013004899A MX 2013004899 A MX2013004899 A MX 2013004899A MX 347981 B MX347981 B MX 347981B
Authority
MX
Mexico
Prior art keywords
family
pan
antibody compositions
antibody composition
directed
Prior art date
Application number
MX2013004899A
Other languages
English (en)
Other versions
MX2013004899A (es
Inventor
Lantto Johan
Wandahl Pedersen Mikkel
Kragh Michael
Jacobsen Helle
K Christensen Ida
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX2013004899A publication Critical patent/MX2013004899A/es
Publication of MX347981B publication Critical patent/MX347981B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a las terapéuticas mejoradas contra los receptores dentro de la familia EGFR/ErbB/HER que interfieren más ampliamente con múltiples miembros de la familia HER (inhibición pan-HER). Más particularmente, la invención está dirigida al uso de las composiciones de anticuerpo para la terapia contra el cáncer humano. Los estudios in vitro han mostrado que las composiciones de anticuerpo de la invención que se dirigen a múltiples receptores de la familia HER, son superiores a las composiciones de anticuerpo que se dirigen únicamente a un receptor de la familia HER.
MX2013004899A 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her. MX347981B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
PCT/IB2011/054834 WO2012059857A2 (en) 2010-11-01 2011-10-31 Pan-her antibody composition

Publications (2)

Publication Number Publication Date
MX2013004899A MX2013004899A (es) 2013-07-15
MX347981B true MX347981B (es) 2017-05-22

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004899A MX347981B (es) 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her.
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.

Country Status (13)

Country Link
US (1) US9217039B2 (es)
EP (3) EP2635604B1 (es)
JP (2) JP6186277B2 (es)
KR (2) KR101773120B1 (es)
AU (2) AU2011324871B2 (es)
CA (2) CA2816519C (es)
DK (1) DK2635604T3 (es)
ES (2) ES2692379T3 (es)
IL (2) IL225953A0 (es)
MX (2) MX347981B (es)
PL (1) PL2635604T3 (es)
TW (1) TW201231066A (es)
WO (2) WO2012059857A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540146C2 (ru) * 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
MX2013010444A (es) * 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
WO2012156975A1 (en) * 2011-05-16 2012-11-22 Yeda Research And Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
KR102558247B1 (ko) * 2011-07-01 2023-07-24 암젠 인크 포유동물 세포 배양
KR102080535B1 (ko) 2011-11-23 2020-02-24 메디뮨 엘엘씨 Her3에 특이적인 결합 분자 및 이의 용도
BR112014024017A8 (pt) * 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
US9527913B2 (en) * 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
RS58705B1 (sr) 2013-09-20 2019-06-28 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
KR102200274B1 (ko) 2014-09-16 2021-01-08 심포젠 에이/에스 항-ｍｅｔ 항체 및 조성물
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
CA3007644A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CA3058960C (en) 2017-04-05 2023-08-29 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
MX2019012032A (es) 2017-05-30 2019-10-30 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
EP3847194A1 (en) * 2018-09-07 2021-07-14 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
KR20210126703A (ko) * 2019-02-14 2021-10-20 메뤼스 엔.페. Egfr, her2 및 her3에 결합하는 결합 모이어티들의 병용물
CN114426578A (zh) * 2019-02-14 2022-05-03 美勒斯公司 结合egfr、her2及her3的结合部分的组合
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20230127306A (ko) 2020-12-31 2023-08-31 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK)세포 관여자

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126303A0 (en) * 1996-03-27 1999-05-09 Genentech Inc Erbb3 antibodies
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
US20070003556A1 (en) * 2003-03-31 2007-01-04 Masayuki Tsuchiya Modified antibodies against cd22 and utilization thereof
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
RU2426795C2 (ru) 2004-07-20 2011-08-20 Симфоген А/С Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии
KR20120068807A (ko) 2004-07-22 2012-06-27 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
CA2676049C (en) 2007-03-01 2018-04-10 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
SI2152872T1 (sl) 2007-05-25 2011-01-31 Symphogen As Postopek za pripravo rekombinantnega poliklonskega proteina
AU2008328370A1 (en) 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
US20110117605A1 (en) 2008-04-23 2011-05-19 Symphogen A/S Methods for Manufacturing a Polyclonal Protein
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
RU2540146C2 (ru) * 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
CN102265152A (zh) 2008-10-06 2011-11-30 西福根有限公司 鉴定和选择用于组合药品的药物候选物
RU2504553C2 (ru) 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
KR20110124369A (ko) * 2009-04-07 2011-11-16 로슈 글리카트 아게 이중특이적 항­ｅｒｂｂ­3／항­ｃ­ｍｅｔ 항체
PL2417156T3 (pl) * 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
EP2425009A4 (en) 2009-04-29 2013-01-23 Trellis Bioscience Llc IMMUNOREACTIVE ENHANCED ANTIBODIES WITH HEREGULINE COUPLE HER3
CN102481367B (zh) * 2009-07-06 2015-04-29 弗·哈夫曼-拉罗切有限公司 结合地高辛配基的双特异性抗体
BR112012003809A2 (pt) 2009-08-21 2019-09-24 Merrimack Pharmaceuticals Inc anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
WO2011044311A2 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
EP2896632B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
JP6039428B2 (ja) * 2010-03-04 2016-12-07 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｈｅｒ２抗体および組成物
SG184452A1 (en) * 2010-04-09 2012-11-29 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.

Also Published As

Publication number Publication date
EP2635605A1 (en) 2013-09-11
TW201231066A (en) 2012-08-01
AU2011324871B2 (en) 2016-05-19
CA2816519C (en) 2019-01-15
AU2011324871A1 (en) 2013-05-09
EP3156421B1 (en) 2018-06-06
US20130287684A1 (en) 2013-10-31
JP2014503189A (ja) 2014-02-13
WO2012059857A3 (en) 2012-07-19
MX2013004897A (es) 2013-07-15
DK2635604T3 (en) 2017-02-27
IL225954A0 (en) 2013-07-31
PL2635604T3 (pl) 2017-09-29
KR20140026337A (ko) 2014-03-05
CA2816519A1 (en) 2012-05-10
AU2011324870A1 (en) 2013-01-31
EP2635604A2 (en) 2013-09-11
WO2012059857A2 (en) 2012-05-10
AU2011324870B2 (en) 2015-01-29
CA2816520C (en) 2017-11-21
MX348637B (es) 2017-06-22
ES2616961T3 (es) 2017-06-14
JP6186277B2 (ja) 2017-08-23
JP6033783B2 (ja) 2016-11-30
ES2692379T3 (es) 2018-12-03
EP2635605A4 (en) 2014-10-22
JP2014503188A (ja) 2014-02-13
US9217039B2 (en) 2015-12-22
KR101862832B1 (ko) 2018-05-30
IL225954B (en) 2018-05-31
IL225953A0 (en) 2013-07-31
EP2635604B1 (en) 2016-11-30
KR20140026336A (ko) 2014-03-05
EP2635605B1 (en) 2018-07-25
CA2816520A1 (en) 2012-05-10
MX2013004899A (es) 2013-07-15
EP3156421A1 (en) 2017-04-19
KR101773120B1 (ko) 2017-08-30
WO2012059858A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
MX347981B (es) Composicion de anticuerpos pan-her.
NZ604003A (en) Monoclonal antibodies against her2
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
NZ626610A (en) Antibodies that bind csf1r
IN2012DN02081A (es)
TN2012000462A1 (en) Anti-cd40 antibodies
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
MX365702B (es) Inhibidores de pirazolil quinoxalina cinasa.
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
MX370017B (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
NZ611866A (en) Spiro-oxindole mdm2 antagonists
SG194701A1 (en) Anti-cd40 antibodies and methods of use
CU20140036A7 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX346336B (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
NZ602992A (en) Prophylaxis of colorectal and gastrointestinal cancer
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
JO3096B1 (ar) الأجسام المضادة لمستقبل ii مضاد tgfb
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
EA201101180A1 (ru) Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
CR20120429A (es) Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello
MX342947B (es) Tratamiento de diabetes tipo 2.

Legal Events

Date Code Title Description
FG Grant or registration